Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 33485464

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2021 Jan 30
First author
Baas P

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2021 Jan 30;397(10272):348-349. doi: 10.1016/S0140-6736(21)00147-1.
    note
    Source null
    related pmid
    33485463
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2021 Apr;18(4):194. doi: 10.1038/s41571-021-00481-5.
    note
    Source null
    related pmid
    33536633
    relationship
    Comment in
  3. citation
    Lancet. 2021 Feb 20;397(10275):670. doi: 10.1016/S0140-6736(21)00369-X.
    note
    Source null
    related pmid
    33610209
    relationship
    Erratum in
  4. citation
    Int J Radiat Oncol Biol Phys. 2021 Jun 1;110(2):257-260. doi: 10.1016/j.ijrobp.2021.02.016.
    note
    Source null
    related pmid
    33989566
    relationship
    Comment in
  5. citation
    Lancet. 2021 Jul 24;398(10297):301-302. doi: 10.1016/S0140-6736(21)00882-5.
    note
    Source null
    related pmid
    34303435
    relationship
    Comment in

Authors and identifiers

  1. name
    Baas P
    type
    Author
  2. name
    Scherpereel A
    type
    Author
  3. name
    Nowak AK
    type
    Author
  4. name
    Fujimoto N
    type
    Author
  5. name
    Peters S
    type
    Author
  6. name
    Tsao AS
    type
    Author
  7. name
    Mansfield AS
    type
    Author
  8. name
    Popat S
    type
    Author
  9. name
    Jahan T
    type
    Author
  10. name
    Antonia S
    type
    Author
  11. name
    Oulkhouir Y
    type
    Author
  12. name
    Bautista Y
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Baas P
    type
    Author
  2. name
    Scherpereel A
    type
    Author
  3. name
    Nowak AK
    type
    Author
  4. name
    Fujimoto N
    type
    Author
  5. name
    Peters S
    type
    Author
  6. name
    Tsao AS
    type
    Author
  7. name
    Mansfield AS
    type
    Author
  8. name
    Popat S
    type
    Author
  9. name
    Jahan T
    type
    Author
  10. name
    Antonia S
    type
    Author
  11. name
    Oulkhouir Y
    type
    Author
  12. name
    Bautista Y
    type
    Author
bibliography ids
  1. nci-bib-455ea69b9e56d2843f87e8df
book metadata
content sha256
caf9c1c7e6d0e345a9056c270b00f65affbd5e56a3187a0603a62ad865f71e60
document type
citation
dois
  1. 10.1016/S0140-6736(20)32714-8
electronic publication date
display
2021 Jan 21
precision
day
year
2021
evidence scope
bibliographic_metadata_only
id
pubmed:33485464
immutable id
pubmed:33485464@caf9c1c7e6d0e345a9056c270b00f65affbd5e56a3187a0603a62ad865f71e60
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10272
name
Lancet (London, England)
nlm unique id
2985213R
pages
375-386
volume
397
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2021 Jan 30;397(10272):348-349. doi: 10.1016/S0140-6736(21)00147-1.
    note
    Source null
    related pmid
    33485463
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2021 Apr;18(4):194. doi: 10.1038/s41571-021-00481-5.
    note
    Source null
    related pmid
    33536633
    relationship
    Comment in
  3. citation
    Lancet. 2021 Feb 20;397(10275):670. doi: 10.1016/S0140-6736(21)00369-X.
    note
    Source null
    related pmid
    33610209
    relationship
    Erratum in
  4. citation
    Int J Radiat Oncol Biol Phys. 2021 Jun 1;110(2):257-260. doi: 10.1016/j.ijrobp.2021.02.016.
    note
    Source null
    related pmid
    33989566
    relationship
    Comment in
  5. citation
    Lancet. 2021 Jul 24;398(10297):301-302. doi: 10.1016/S0140-6736(21)00882-5.
    note
    Source null
    related pmid
    34303435
    relationship
    Comment in
outcomes validated
false
pmid
33485464
provenance
batch id
9bca82d1bba2b27adc79
provider
NCBI PubMed ESummary
record sha256
bf4ba2c1a155c36b690d3673f19fc3df58ee9e2cfe1f07a1abf66b11b7e8bcf8
response sha256
c8a4853c65a45038af15f5ade3970763bfa121cf5c68bafcc52c3a06860d0211
retrieved at
2026-09-09T23:47:56.131551+00:00
publication date
display
2021 Jan 30
precision
day
year
2021
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/33485464/
title
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.

Preserved source evidence · Not medical advice